Renal Cell Carcinoma

In patients with clear cell renal cell carcinoma who had been treated with an immune checkpoint inhibitor in prior lines of therapy, lenvatinib in combination with everolimus was found to be safe and effective.

Ulka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

In an interview with Targeted Oncology, Andrea Apolo, MD discussed the impact of the combination of nivolumab and cabozantinib as a new treatment for patients with advanced renal cell carcinoma.

The FDA has granted approval to the combination of nivolumab and cabozantinib as treatment of advanced renal cell carcinoma in the frontline setting.

Elizabeth Wulff-Burchfield, MD, discusses the role of immune checkpoint inhibitor combination therapy in metastatic renal cell carcinoma.

The role of immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors appear encouraging for the treatment of patients with kidney cancer following recent research on targeting von Hippel-Lindau disease-associated renal cell carcinoma.

Pazopanib, a tyrosine kinase inhibitor, is active and well-tolerated in patients with poor-risk metastatic clear cell renal cell carcinoma with no new safety signal observed, according to results from the phase 4 FLIPPER clinical trial.

Treatment with telaglenastat in combination with cabozantinib did not improve progression-free survival in patients with advanced or metastatic renal cell carcinoma when compared with cabozantinib alone, missing the primary end point of the phase 2 CANTANA clinical trial.

Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.

The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau disease-associated clear cell renal cell carcinoma and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology.

Toni Choueiri, MD, discusses nivolumab, ipilimumab, and cabozantinib combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma.

During a Targeted Oncology Case Based Peer Perspectives event, Marc Matrana, MD, MS, discussed the case of a 62-year-old male patients with renal cell carcinoma.

In an interview with Targeted Oncology, Chung-Han (Joe) Lee, MD, PhD, discussed the use of different targeted therapy and immunotherapy strategies for the treatment of patients with metastatic kidney cancer.

In an interview with Targeted Oncology, Thomas E. Hutson, DO, PharmD, discussed the difficult-to-treat nccRCC patient population and the promise of lenvatinib plus everolimus, as well as other combination regimens.

Lenvatinib in combination with everolimus improved progression-free survival in patients with advanced renal cell carcinoma compared with sunitinib, meeting the primary end point of the phase 3 KEYNOTE-581/CLEAR clinical trial. Pembrolizumab added to lenvatinib, another experimental arm of the trial, also achieved a satisfactory overall response rate, meeting a key secondary end point.

Investigators of the CheckMate 920 trial found no differences in safety signals or responses with modified dosing of nivolumab and ipilimumab compared with the standard dose in patients with advanced renal cell carcinoma treated in the frontline.

During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.

Findings from a phase 2 trial evaluating lenvatinib given at 2 different starting doses, 14 mg versus 18 mg, in combination with everolimus, suggest the lower dose is similar to the standard dose in terms of efficacy and safety with minimal differences observed between the 2 arms.

Significant overall survival and progression-free survival benefits were observed with combination regimens containing immunotherapy in combination with a tyrosine kinase inhibitor, along with tolerable safety in patients with renal cell carcinoma to Suzanne Cole, MD, FACP noted, however, that the cost of these combination can dim the light on the advantages.

Elizabeth Wulff-Burchfield, MD, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.

In patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy, the combination of lenvatinib and pembrolizumab achieved antitumor responses, according to results from a phase 2 trial.

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed key results from the CheckMate-9ER trial in advanced renal cell carcinoma, as well as ongoing trials with the potential to move the landscape further along.

Lenvatinib plus everolimus demonstrated anti-tumor activity as treatment of patients with advanced non-clear cell renal cell carcinoma in the frontline setting, according to findings from a phase 2 clinical trial.

Based on results from the phase 2 OMNIVORE study, the response-based strategy achieved no complete responses and a low partial response/complete response conversion in advanced renal cell carcinoma.

During a Targeted Oncology Case Based Peer Perspective event, Chung-Han Lee, MD, PhD, discussed the case of a 57-year-old woman with clear cell renal cell carcinoma.